Literature DB >> 7556117

Acute mountain sickness relates to sea-level partial pressure of oxygen.

G Savourey1, C Moirant, J Eterradossi, J Bittel.   

Abstract

The aim of this study was to clarify the relationships between acute mountain sickness (AMS), studied during an expedition in the Andes, and some physiological parameters determined before the expedition, i.e. biometrical characteristics of the subjects [maximal oxygen consumption (VO2max), body fat content, body mass index], functional pulmonary tests (forced vital capacity, forced expiratory volume at the first second), ventilatory or cardiac responses measured at 4,500 m [hypoxic ventilatory responses (HVR) 4,500 and hypoxic cardiac responses (HCR) 4,500, respectively), cold pressor responses. To achieve this objective, 11 subjects were firstly submitted to a hypobaric poïkilocapnic hypoxic test (589 hPa, 4,500 m) at rest and during exercise to study minute volume, respiratory frequency, end tidal partial pressure of O2 (PETO2) and CO2, HVR 4,500, HCR 4,500 and to a cold pressor test of the hand (5 min in 5 degrees C cold water) to study heart rate, blood pressure and skin temperature changes. The AMS was assessed daily by questionnaire during a 12-day expedition in the Andes following both Hackett's method and Environmental Symptoms Questionnaire (modified ESQ II). Maximal AMS-Hackett score, maximal AMS-ESQ score and mean AMS-ESQ score were defined. The quantifications of AMS following the two methods were correlated. No significant relationships were observed between mean AMS-ESQ score and the biometrical characteristics of the subjects, the functional pulmonary tests, HVR 4,500, HCR 4,500 or the cold pressor responses. However, it appeared that the mean AMS-ESQ score was correlated with PETO2 measured at rest and during exercise (50% VO2max) both in hypoxia and normoxia. A closer linear relationship was observed during the exercise in normoxia (r = -0.92, P < 0.0001). These results could suggest that AMS was related to a relative alveolar hypoventilation more in relation to breathing pattern than HVR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7556117     DOI: 10.1007/bf00634374

Source DB:  PubMed          Journal:  Eur J Appl Physiol Occup Physiol        ISSN: 0301-5548


  32 in total

1.  Chemoreflexes in breathing.

Authors:  P DEJOURS
Journal:  Physiol Rev       Date:  1962-07       Impact factor: 37.312

2.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

3.  Acute mountain sickness susceptibility, fitness and hypoxic ventilatory response.

Authors:  J S Milledge; J M Beeley; J Broome; N Luff; M Pelling; D Smith
Journal:  Eur Respir J       Date:  1991-09       Impact factor: 16.671

4.  Ventilation response to hypoxia and acute mountain sickness.

Authors:  A B King; S M Robinson
Journal:  Aerosp Med       Date:  1972-04

5.  Acute mountain sickness: reproducibility of its severity and duration in an individual.

Authors:  S M Robinson; A B King; V Aoki
Journal:  Aerosp Med       Date:  1971-07

6.  Procedures for the measurement of acute mountain sickness.

Authors:  J B Sampson; A Cymerman; R L Burse; J T Maher; P B Rock
Journal:  Aviat Space Environ Med       Date:  1983-12

7.  Chemoreceptor sensitivity and maladaptation to high altitude in man.

Authors:  L Mathew; P M Gopinathan; S S Purkayastha; J Sen Gupta; H S Nayar
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1983

8.  Accentuated hypoxemia at high altitude in subjects susceptible to high-altitude pulmonary edema.

Authors:  T M Hyers; C H Scoggin; D H Will; R F Grover; J T Reeves
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1979-01

9.  Hypoxic ventilatory drive in normal man.

Authors:  J V Weil; E Byrne-Quinn; I E Sodal; W O Friesen; B Underhill; G F Filley; R F Grover
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

10.  Hypoxic ventilatory response and acute mountain sickness.

Authors:  J S Milledge; P S Thomas; J M Beeley; J S English
Journal:  Eur Respir J       Date:  1988-12       Impact factor: 16.671

View more
  7 in total

Review 1.  Neuropsychological functioning associated with high-altitude exposure.

Authors:  Javier Virués-Ortega; Gualberto Buela-Casal; Eduardo Garrido; Bernardino Alcázar
Journal:  Neuropsychol Rev       Date:  2004-12       Impact factor: 7.444

2.  Prediction of the susceptibility to AMS in simulated altitude.

Authors:  Martin Burtscher; Christoph Szubski; Martin Faulhaber
Journal:  Sleep Breath       Date:  2008-05       Impact factor: 2.816

3.  Recruitment of non-perfused sublingual capillaries increases microcirculatory oxygen extraction capacity throughout ascent to 7126 m.

Authors:  Matthias Peter Hilty; Tobias Michael Merz; Urs Hefti; Can Ince; Marco Maggiorini; Jacqueline Pichler Hefti
Journal:  J Physiol       Date:  2019-03-28       Impact factor: 5.182

4.  Pre-adaptation, adaptation and de-adaptation to high altitude in humans: cardio-ventilatory and haematological changes.

Authors:  G Savourey; N Garcia; Y Besnard; A Guinet; A M Hanniquet; J Bittel
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

5.  Normo or hypobaric hypoxic tests: propositions for the determination of the individual susceptibility to altitude illnesses.

Authors:  Gustave Savourey; Jean-Claude Launay; Yves Besnard; Angélique Guinet-Lebreton; Antonia Alonso; Fabien Sauvet; Cyprien Bourrilhon
Journal:  Eur J Appl Physiol       Date:  2007-02-24       Impact factor: 3.346

6.  Susceptibility to hypoxia and breathing control changes after short-term cold exposures.

Authors:  Lyudmila T Kovtun; Mikhail I Voevoda
Journal:  Int J Circumpolar Health       Date:  2013-08-05       Impact factor: 1.228

7.  The effect of acute intermittent hypoxia on postprandial triglyceride levels in humans: a randomized crossover trial.

Authors:  Renée Morin; Jean-François Mauger; Ruwan Amaratunga; Pascal Imbeault
Journal:  J Transl Med       Date:  2021-06-22       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.